**Disclaimer:** This article is for informational purposes only and does not constitute legal, tax, financial, or investment advice. Laws and regulations vary by jurisdiction and change frequently. Always consult a qualified professional before making any decision. On 15 May 2026, the Central Drugs Standard Control Organisation (CDSCO) released a revised Quality-by-Design (QbD) filing protocol for Active Pharmaceutical Ingredients (APIs), effective immediately.
The new pathway streamlines dossier submission by consolidating process validation and stability data requirements into a single pre-approval phase. For API manufacturers, this represents both an opportunity to expedite approvals and a compliance obligation: applications filed after 15 June 2026 must comply with the revised structure, or risk rejection and resubmission delays.
Market signals
CDSCO's revised protocol merges process validation reports and stage-wise stability data into one integrated dossier module. Manufacturers can now submit design space justification and control strategy in a single technical file, reducing the multi-stage submission cycle by 8–12 weeks.
APIs manufactured at ≤100 kg annual scale are now eligible for simplified QbD dossiers, omitting full process characterisation studies if raw material and in-process controls meet defined risk thresholds. This lowers compliance cost for MSME API suppliers.
All QbD applications must be filed through CDSCO's eCTD portal (live since April 2026); paper dossiers are no longer accepted. Manufacturers must ensure IT infrastructure and eCTD-compliant document formatting before submitting.
Under India's Drugs and Cosmetics Act, 1940, CDSCO approval is mandatory for all APIs intended for pharmaceutical use. The revised QbD protocol is now a regulatory requirement—not optional. Manufacturers submitting dossiers after 15 June 2026 must comply or face rejection. Vinayakam Consultants advises API makers to audit their current dossier templates against the revised CTD structure, confirm eCTD portal access and digital certification readiness, and—if risk-based eligibility applies—engage a qualified pharmacopeial consultant to prepare simplified design-space justifications. We help clients map existing stability and validation data to the new consolidated format, avoiding costly resubmissions.
Your action checklist
- Audit your current QbD dossier template against CDSCO's revised eCTD module structure (issued 15 May 2026) and identify gaps in design-space documentation or control-strategy alignment.
- Verify eCTD portal account access, digital certificate validity (FDA Form 1571-equivalent), and document XML formatting compliance before 15 June 2026.
- If manufacturing scale is ≤100 kg/year, prepare a risk-based classification table (raw material, in-process control linkage) to claim simplified dossier eligibility and reduce submission burden.
- Engage your regulatory affairs team or an external consultant to consolidate existing process validation and stability reports into the single pre-approval module required under the new pathway, and prepare a consolidated submission timeline.
Frequently asked questions
The revised QbD pathway is effective immediately from 15 May 2026. All API applications filed after 15 June 2026 must comply with the new structure or face rejection.
The revised protocol consolidates process validation and stability data into a single integrated dossier module, reducing submission cycles by 8–12 weeks and allowing manufacturers to submit design space justification and control strategy together.
No. All QbD applications must be filed through CDSCO's eCTD portal (live since April 2026); paper dossiers are no longer accepted.